Why Novartis Stock Is Down Today Despite Topping Q2 Estimates

By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit guidance for the remainder of the year was encouraging, lifted from its previously announced expectations.And yet, Novartis stock is down 4.5% as of 1:55 p.m. ET Thursday, according to data from S&P Global Market Intelligence.What gives? Blame the company's decision to bow out of one particular sliver of the cancer market, mostly.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool